SCHEMBL31366692

SCHEMBL31366692

CC(C)(C)OC(=O)NCCCc1ccc(Cl)cc1N

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.53
ALDH1A1 P00352 3/20 0.51
HPGD P15428 2/20 0.51
HTT P42858 2/20 0.51
KDM4E B2RXH2 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
TP53 P04637 1/20 0.50
GLA P06280 1/20 0.50
MAPT P10636 1/20 0.50
XBP1 P17861 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
HSD17B10 Q99714 1/20 0.50
DRD2 P14416 5/20 0.47
LMNA P02545 1/20 0.44
BRD4 O60885 1/20 0.44
CA1 P00915 4/20 0.44
CA2 P00918 4/20 0.44
CA12 O43570 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30313133 0.92 ALDH1A1 (0.55) IDO1ALDH1A1HPGDHTTKDM4E
SCHEMBL3658450 0.92 ALDH1A1 (0.55) IDO1ALDH1A1HPGDHTTKDM4E
SCHEMBL21987982 0.84 IDO1 (0.51) IDO1ALDH1A1HPGDHTTKDM4E
SCHEMBL7531330 0.82 NQO2 (0.48) IDO1MEN1KMT2ADRD2LMNA
SCHEMBL4573884 0.81 CA12 (0.51) IDO1ALDH1A1KDM4ESMN1; SMN2MEN1
SCHEMBL12330486 0.80 TDP1 (0.46) IDO1KDM4EMEN1KMT2ABRD4
SCHEMBL19175055 0.79 CA1 (0.45) MEN1KMT2ANPSR1CA1CA2
SCHEMBL21077910 0.79 DRD2 (0.55) IDO1ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL6921462 0.79 IDO1 (0.54) IDO1ALDH1A1HPGDHTTKDM4E
SCHEMBL15291946 0.78 IDO1 (0.47) IDO1ALDH1A1HPGDHTTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240408093-A1 HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE HALDA THERAPEUTICS OPCO, INC. 2024-12-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240408093-A1 HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE FGFR3, FGFR1, ERBB3 IDO1 3487/4885ALDH1A1 4423/4885HPGD 4233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.